Re: Autoimmune diseases

My simple reply to this is -
There is not enough dosage to cause damage and no damage has been seen in the human trial below also no-one has reported this problem so it's not a significant risk

Potential downward trends were noted in the following categories : macrophage intracellular TNF-α secretion, and a decrease in the number of circulating CD14+/DR+ cells. It has been reporte that immune paralysis results when the number of circulating CD14+/DR+ cells decreases to such an extent as to reach a threshold value. No obvious changes were noted in T-cell PHA activation values or HIV load as measured by the HIV bDNA assay (most of the patients had no detectable HIV thoughout the study). Results of the RBC survival studies showed no evidence for hemolysis in response to the treatment


http://www.wipo.int/pctdb/en/wo.jsp?wo=1999017787&IA=WO1999017787&DISPLAY=DESC